BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3896295)

  • 1. Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non-Hodgkin's lymphoma.
    Philip T; Biron P; Maraninchi D; Goldstone AH; Herve P; Souillet G; Gastaut JL; Plouvier E; Flesh Y; Philip I
    Br J Haematol; 1985 Aug; 60(4):599-609. PubMed ID: 3896295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
    Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
    Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
    Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
    J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Massive therapy and autologous bone marrow transplantation in very bad prognosis Burkitt's lymphoma.
    Philip T; Biron P; Philip I; Favrot M; Souillet G; Philippe N; Hervé P; Plouvier E; Bernard JL; Raybaud C
    IARC Sci Publ; 1985; (60):419-34. PubMed ID: 3905593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin's malignant lymphoma with a very bad prognosis.
    Philip T; Biron P; Hervé P; Dutou L; Ehrsam A; Philip I; Souillet G; Plouvier E; Le Mevel A; Philippe N
    Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1371-9. PubMed ID: 6357803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.
    Freedman AS; Takvorian T; Neuberg D; Mauch P; Rabinowe SN; Anderson KC; Soiffer RJ; Spector N; Grossbard M; Robertson MJ
    J Clin Oncol; 1993 May; 11(5):931-6. PubMed ID: 8487057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
    Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM
    J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy and non-frozen autologous bone marrow transplantation in relapsed advanced lymphomas or those resistant to conventional chemotherapy.
    Carella AM; Santini G; Giordano D; Frassoni F; Nati S; Congiu A; Occhini D; Rossi E; Martinengo M; Damasio E
    Cancer; 1984 Dec; 54(12):2836-9. PubMed ID: 6388818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors.
    Verdonck LF; Dekker AW; Vendrik PJ; van Kempen ML; Schornagel JH; Rozenberg-Arska M; de Gast GC
    Cancer; 1987 Aug; 60(3):289-95. PubMed ID: 3297283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
    Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Lazarus HM; Crilley P; Ciobanu N; Creger RJ; Fox RM; Shina DC; Bulova SI; Gucalp R; Cooper BW; Topolsky D
    J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy.
    Gribben JG; Goldstone AH; Linch DC; Taghipour G; McMillan AK; Souhami RL; Earl H; Richards JD
    J Clin Oncol; 1989 Nov; 7(11):1621-9. PubMed ID: 2809678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.
    O'Brien ME; Milan S; Cunningham D; Jones AL; Nicolson M; Selby P; Hickish T; Hill M; Gore ME; Viner C
    Br J Cancer; 1996 May; 73(10):1272-7. PubMed ID: 8630292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry.
    Williams CD; Pearce R; Taghipour G; Green ES; Philip T; Goldstone AH
    J Clin Oncol; 1994 Nov; 12(11):2415-22. PubMed ID: 7964958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.